Killing tumor cells through their surface β2-microglobulin or major histocompatibility complex class I molecules

Cancer

Volumn 116, Issue 7, 2010, Pages 1638-1645

  Yang, Jing ^a   Yi, Qing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

2 microglobulin; Major histocompatibility complex class I; Monoclonal antibodies; Signaling pathways; Tumor cell apoptosis

Indexed keywords

ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BETA 2 MICROGLOBULIN ANTIBODY; CASPASE 9; INTERLEUKIN 6 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE 9; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE B; PROTEIN KINASE LYN; SOMATOMEDIN C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; HEMATOPOIETIC CELL; HUMAN; LEUKEMIA; LIPID RAFT; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MITOCHONDRION; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOLID TUMOR; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BETA 2-MICROGLOBULIN; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS I; MEMBRANE MICRODOMAINS; MICE; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77950292477     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24953     Document Type: Review

References (62)

1. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003;3:952-961.
2. Buus S. MHC restricted antigen presentation and T cell recognition. Dan Med Bull. 1994;41:345-358.
3. Bjorkman PJ, Burmeister WP. Structures of 2 classes of MHC molecules elucidated: crucial differences and similarities. Curr Opin Struct Biol. 1994;4:852-856.
4. Strominger JL. Human histocompatibility proteins. Immunol Rev. 2002;185:69-77.
5. Natarajan K, Li H, Mariuzza RA, et al. MHC class I molecules, structure and function. Rev Immunogenet. 1999;1:32-146.
6. Scupoli MT, Sartoris S, Tosi G, et al. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens. 1996;48:301-311.
7. Algarra I, Collado A, Garrido F. Altered MHC class I antigens in tumors. Int J Clin Lab Res. 1997;27:95-102.
8. Seliger B, Harders C, Wollscheid U, et al. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. Exp Hematol. 1996;24:1275-1279.
9. Bubenik J. MHC class I down regulation, tumour escape from immune surveillance and design of therapeutic strategies. Folia Biol (Praha). 2005;51:1-2.
10. Musarurwa C, Matarira HT. Beta-2-microglobulin in multiple myeloma. Cent Afr J Med. 2004;50:19-20.
11. Fishman D, Elhyany S, Segal S. Non-immune functions of MHC class I glycoproteins in normal and malignant cells. Folia Biol (Praha). 2004;50:35-42.
12. Tanaka K, Kasahara M. The MHC class I ligand-generating system: roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Immunol Rev. 1998;163:161-176.
13. Skov S, Nielsen M, Bregenholt S, et al. Activation of Stat-3 is involved in the induction of apoptosis after ligation of major histocompatibility complex class I molecules on human Jurkat T cells. Blood. 1998;91:3566-3573.
14. Skov S, Bregenholt S, Claesson MH. MHC class I ligation of human T cells activates the ZAP70 and p56lck tyrosine kinases, leads to an alternative phenotype of the TCR/CD3 zeta-chain, and induces apoptosis. J Immunol. 1997;158:3189-3196.
15. Ruhwald M, Pedersen AE, Claesson MH. MHC class I cross-talk with CD2 and CD28 induces specific intracellular signalling and leads to growth retardation and apoptosis via a p56(lck)-dependent mechanism. Exp Clin Immunogenet. 1999;16:199-211.
16. Skov S, Odum N, Claesson MH. MHC class I signaling in T cells leads to tyrosine kinase activity and PLC-gamma 1 phosphorylation. J Immunol. 1995;154:1167-1176.
17. Lamberth K, Claesson MH. Ligation of major histocompatibility complex class I antigens (MHC-I) prevents apoptosis induced by Fas or SAPK/JNK activation in T-lymphoma cells. Tissue Antigens. 2001;58:171-180.
18. Gur H, Geppert TD, Wacholtz MC, et al. The cytoplasmic and the transmembrane domains are not sufficient for class I MHC signal transduction. Cell Immunol. 1999;191:105-116.
19. Gur H, el-Zaatari F, Geppert TD, et al. Analysis of T cell signaling by class I MHC molecules: the cytoplasmic domain is not required for signal transduction. J Exp Med. 1990;72:1267-1270.
20. Stagsted J, Reaven GM, Hansen T, et al. Regulation of insulin receptor functions by a peptide derived from a major histocompatibility complex class I antigen. Cell. 1990;62:297-307.
21. Stagsted J, Hansen T, Roth RA, et al. Correlation between insulin receptor occupancy and tyrosine kinase activity at low insulin concentrations and effect of major histocompatibility complex class I-derived peptide. J Pharmacol Exp Ther. 1993;267:997-1001.
22. Stagsted J, Olsson L, Holman GD, et al. Inhibition of internalization of glucose transporters and IGF-II receptors. Mechanism of action of MHC class I-derived peptides which augment the insulin response in rat adipose cells. J Biol Chem. 1993;268:22809-22813.
23. Centrella M, McCarthy TL, Canalis E. Beta 2-microglobulin enhances insulin-like growth factor I receptor levels and synthesis in bone cell cultures. J Biol Chem. 1989;264:18268-18271.
24. Schreiber AB, Schlessinger J, Edidin M. Interaction between major histocompatibility complex antigens and epidermal growth factor receptors on human cells. J Cell Biol. 1984;98:725-731.
25. Stagsted J, Ziebe S, Satoh S, et al. Insulinomimetic effect on glucose transport by epidermal growth factor when combined with a major histocompatibility complex class I-derived peptide. J Biol Chem. 1993;268:1770-1774.
26. Sharon M, Gnarra JR, Baniyash M, Leonard WJ. Possible association between IL-2 receptors and class I HLA molecules on T cells. J Immunol. 1988;141:3512-3515.
27. Genestier L, Paillot R, Bonnefoy-Berard N, et al. Fas-independent apoptosis of activated T cells induced by antibodies to the HLA class I alpha1 domain. Blood. 1997;90:3629-3639.
28. Genestier L, Meffre G, Garrone P, et al. Antibodies to HLA class I alpha1 domain trigger apoptosis of CD40-activated human B lymphocytes. Blood. 1997;90:726-735.
29. Matsuoka S, Tsurui H, Abe M, et al. A monoclonal antibody to the alpha2 domain of murine major histocompatibility complex class I that specifically kills activated lymphocytes and blocks liver damage in the concanavalin A hepatitis model. J Exp Med. 2003;198:497-503.
30. Woodle ES, Smith DM, Zhou N. Class I MHC mediates programmed cell death in human lymphoid cells. Transplantation. 1997;64:140-146.
31. Smith DM, Bluestone JA, Jeyarajah DR, et al. Inhibition of T cell activation by a monoclonal antibody reactive against the alpha 3 domain of human MHC class I molecules. J Immunol. 1994;153:1054-1067.
32. Bataille R, Durie BG, Grenier J. Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol. 1983;55:439-447.
33. Cooper EH, Plesner T. Beta-2-microglobulin review: its relevance in clinical oncology. Med Pediatr Oncol. 1980;8:323-334.
34. Molica S, Levato D, Cascavilla N, et al. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol. 1999;62:117-122.
35. Rajkumar SV, Fonseca R, Lacy MQ, et al. A. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma. Bone Marrow Transplant. 1999;23:1261-1266.
36. Sato Y, Kuno H, Kaji M, et al. Serum beta2-microglobulin reflects increased bone resorption in immobilized stroke patients. Am J Phys Med Rehabil. 2001;80:19-24.
37. Balint E, Marshall CF, Sprague SM. Role of interleukin-6 in beta2-microglobulin-induced bone mineral dissolution. Kidney Int. 2000;57:1599-1607.
38. Ohashi K. Pathogenesis of beta2-microglobulin amyloidosis. Pathol Int. 2001;51:1-10.
39. Yang J, Qian J, Wezeman M, et al. Targeting beta-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006;10:295-307.
40. Yang J, Cao Y, Hong S, et al. Human like-mouse models for testing the efficacy and safety of anti-beta2-microblobulin monoclonal antibodies to treat myeloma. Clin Cancer Res. 2009;3:951-959.
41. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550-6565.
42. Kovacs MJ, Reece DE, Marcellus D, et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma - NCIC CTG IND.145. Invest New Drugs. 2006; 24:529-535.
43. Huang WC, Wu D, Xie Z, et al. Beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Res. 2006;66:9108-9116.
44. Sekimoto E, Ozaki S, Ohshima T, et al. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res. 2007;67:1184-1192.
45. Rasmuson T, Grankvist K, Ljungberg B. Serum beta 2-microglobulin and prognosis of patients with renal cell carcinoma. Acta Oncol. 1996;35:479-482.
46. Selli C, Cozzolino F, Carini M, et al. Serum beta 2 microglobulin levels in patients with renal cell carcinoma. Urol Res. 1984;12:261-263.
47. Staab HJ, Anderer FA, Hiesche K, et al. Is serum beta 2-microglobulin a tumor marker in gastrointestinal cancer? Clin Chim Acta. 1980;106:309-317.
48. Chen HL, Gabrilovich D, Virmani A, et al. Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer. Int J Cancer. 1996;67:756-763.
49. Papaioannou D, Geggie P, Klassen J. Study of serum beta-2 microglobulin levels in breast cancer patients. Clin Chim Acta. 1979;99:37-41.
50. Nomura T, Huang WC, Zhau HE, et al. Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res. 2006;12:7294-7305.
51. Nomura T, Huang WC, Seo S, et al. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol. 2007;178:292-300.
52. Freeman MR. Beta2 microglobulin: a surprising therapeutic target for prostate cancer and renal cell carcinoma. J Urol. 2007;178:10-11.
53. Huang WC, Havel JJ, Zhau HE, et al. Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clin Cancer Res. 2008;14:5341-5347.
54. Skov S. Intracellular signal transduction mediated by ligation of MHC class I molecules. Tissue Antigens. 1998;51:215-223.
55. Tscherning T, Claesson MH. Signal transduction via MHC class-I molecules in T cells. Scand J Immunol. 1994;39:117-121.
56. Yang J, Zhang X, Wang J, et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood. 2007;110:3028-3035.
57. Woodle ES, Smith DM, Bluestone JA, et al. Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated pathway. J Immunol. 1997;158:2156-2164.
58. Podar K, Tai YT, Cole CE, et al. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003;278:5794-5801.
59. Cherukuri A, Dykstra M, Pierce SK. Floating the raft hypothesis: lipid rafts play a role in immune cell activation. Immunity. 2001;14:657-660.
60. Unruh TL, Li H, Mutch CM, et al. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. Immunology. 2005;116:223-232.
61. Nagy Z, Mooney N. A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules. J Mol Med. 2003;81:757-765.
62. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84:3063-3070.